The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDestiny Pharma. Share News (DEST)

Share Price Information for Destiny Pharma. (DEST)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.25
Bid: 18.00
Ask: 18.50
Change: 0.00 (0.00%)
Spread: 0.50 (2.778%)
Open: 18.25
High: 18.25
Low: 18.25
Prev. Close: 18.25
DEST Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Destiny Pharma jumps on positive nasal gel study

Mon, 29th Mar 2021 09:59

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

----------

AIM - WINNERS

----------

Destiny Pharma PLC, up 27% at 203.20 pence, 12-month range 29.1p-250p. 12-month high was hit earlier on Monday. The biotechnology firm reports data which found its nasal gel may be effective in preventing post-surgical bacterial infections. Results from a Phase 2b trial of XF-73 meet the primary efficacy endpoint. It shows a 99.5% decline in staphylococcus aureus bacterial nasal carriage, a "very effective reduction by accepted clinical measures", Destiny says. Compared to a placebo, it shows a greater than 99% reduction.

----------

Europa Metals Ltd, up 13% at 12.98p, 12-month range 4.25p-30.00p. The Australian mining projects developer reports a widened interim pretax loss but says there does not currently appear to be any material impact on the company or any significant uncertainties as a result of the coronavirus pandemic. Posts pretax loss of AUD1.7 million - about USD1.3 million - for the six months to the end of 2020, compared to AUD1.4 million loss a year earlier.

----------

Blackbird PLC, up 10% at 26.95p, 12-month range 9.5p-29.65p. The developer and seller of cloud video editing platforms says BT has chosen it for "ultra-fast and sustainable" cloud native video editing and publishing. Blackbird will work in conjunction with Pete Harvey, BT's head of digital media content operations. Harvey will use Blackbird to access and edit multiple live broadcast streams of sports and other content for the "fast" production of assets for downstream distribution to over the top and video on demand channels.

----------

AIM - LOSERS

----------

RA International Group PLC, down 16% at 41.24p, 12-month range 27.2p-72.5p. The remote site services provider notes a further escalation in hostile activity in the Cabo Delgado province, northern Mozambique, near to where the company's operations are based. Says security concerns, compounded by the pandemic and extreme weather, have led to delays to the overall energy related project in the region and to the suspension of its contract to build and operate an 1,800-person camp, where an extension of the initial two-year tenancy contract is under negotiation. "Given the escalation in hostilities in the area in recent days, the directors of the company now expect there will be further delays in the project that are likely to impact on the overall financial performance of the company in the current financial year. This impact is expected, at the current time, to be up to USD10 million of revenue, which the directors expect will now be recognised in a later financial period," says Chief Executive Soraya Narfeldt.

----------

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
17 Dec 2019 16:06

Destiny Pharma Says New Guidelines Prove Lead Product Marketability

Destiny Pharma Says New Guidelines Prove Lead Product Marketability

Read more
2 Dec 2019 15:57

Destiny Pharma Appoints Former Polyphor Medical Chief To Board

Destiny Pharma Appoints Former Polyphor Medical Chief To Board

Read more
16 Oct 2019 14:48

Destiny Pharma pleased with latest XF-73 results at it proceeds with next phase

(Sharecast News) - Clinical stage biotechnology company Destiny Pharma reported on the publication of results from a positive phase 1 clinical study in 60 healthy United States volunteers using a nasal gel formulation of its lead drug, XF-73 (exeporfinium chloride), on Wednesday.

Read more
16 Oct 2019 11:36

Destiny Pharma's XF-73 Associated With Reduced Staphylococcus Aureus

Destiny Pharma's XF-73 Associated With Reduced Staphylococcus Aureus

Read more
23 Sep 2019 16:09

Destiny Pharma Says Non-Executive Joe Eagle Steps Down From Board

Destiny Pharma Says Non-Executive Joe Eagle Steps Down From Board

Read more
23 Sep 2019 12:12

Destiny Pharma Interim Loss Narrows On Smaller Share Option Charge

Destiny Pharma Interim Loss Narrows On Smaller Share Option Charge

Read more
10 Sep 2019 14:16

Destiny Pharma Collaboration With University Of Sheffield Wins Funding

(Alliance News) - Destiny Pharma PLC on Tuesday said it has been awarded a grant along with the University of Sheffield for their research collaboration on drug-resistant infections.Shares

Read more
9 Apr 2019 11:17

Destiny Pharma Annual Loss Doubles On Higher Costs, Confident Outlook

LONDON (Alliance News) - Destiny Pharma PLC on Tuesday reported a significantly widened annual loss as expenses surged in the run-up to the development of its lead candidate.For 2018, the a

Read more
9 Apr 2019 09:32

Destiny Pharma 'well funded' despite wider loss

(Sharecast News) - Destiny Pharma on Tuesday reported a wider annual loss as it increased research and development costs, although the company is "well funded" through to the second half of next year.

Read more
2 Apr 2019 16:06

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 3 April AAFull Year ResultsCMC MarketsTrading GroupTrading Year Year 4

Read more
27 Mar 2019 11:53

Destiny Pharma, MedPharm To Develop New XF-Platform Drug Formulations

LONDON (Alliance News) - Destiny Pharma PLC on Wednesday said it has partnered with MedPharm to develop new formulations of its XF-platform compounds.MedPharm is a contract provider of and

Read more
28 Jan 2019 11:46

Destiny Pharma Gets Positive Results From Second Phase Trial Of XF-73

LONDON (Alliance News) - Destiny Pharma PLC on Monday reported positive results in a second phase 1 clinical study examining the anti-irritation features of its XF-73 nasal gel.The study, a

Read more
28 Jan 2019 10:39

Destiny Pharma sees success in latest trial of XF-73 nasal gel

(Sharecast News) - Clinical stage biotechnology company Destiny Pharma announced positive data and the non-irritant classification for its XF-73 nasal gel on Monday.

Read more
25 Jan 2019 10:58

Destiny Pharma leaps on £1.6m grant and UK-China collaboration

(Sharecast News) - Destiny Pharma jumped on Friday after being awarded funding of up to £1.6m from a collaboration established under the UK-China AMR grant fund.

Read more
25 Jan 2019 09:53

Destiny Pharma Gets Funding For Antimicrobial Resistance Research

LONDON (Alliance News) - Destiny Pharma PLC said Friday that it has secured a GBP1.6 million grant for examining novel drugs to prevent, control and eradicate life threatening bacteria or without

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.